Seven Eight Capital’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-64,883
| Closed | -$7.48M | – | 408 |
|
|
2024
Q3 | $7.48M | Buy |
64,883
+57,021
| +725% | +$6.57M | 0.67% | 7 |
|
|
2024
Q2 | $1.08M | Buy |
7,862
+6,190
| +370% | +$852K | 0.11% | 333 |
|
|
2024
Q1 | $231K | Sell |
1,672
-5,543
| -77% | -$764K | 0.02% | 562 |
|
|
2023
Q4 | $951K | Buy |
+7,215
| New | +$951K | 0.11% | 271 |
|
|
2023
Q3 | – | Sell |
-6,430
| Closed | -$606K | – | 689 |
|
|
2023
Q2 | $606K | Buy |
+6,430
| New | +$606K | 0.1% | 273 |
|
|
2023
Q1 | – | Sell |
-1,804
| Closed | -$215K | – | 550 |
|
|
2022
Q4 | $215K | Buy |
+1,804
| New | +$215K | 0.06% | 363 |
|
|
2021
Q4 | – | Sell |
-3,616
| Closed | -$347K | – | 603 |
|
|
2021
Q3 | $347K | Buy |
+3,616
| New | +$347K | 0.03% | 483 |
|
|
2020
Q4 | – | Sell |
-20,300
| Closed | -$1.95M | – | 554 |
|
|
2020
Q3 | $1.95M | Buy |
+20,300
| New | +$1.95M | 0.42% | 36 |
|
|
2020
Q1 | – | Sell |
-66,038
| Closed | -$7.1M | – | 618 |
|
|
2019
Q4 | $7.1M | Buy |
66,038
+8,969
| +16% | +$964K | 0.38% | 66 |
|
|
2019
Q3 | $5.14M | Buy |
+57,069
| New | +$5.14M | 0.27% | 106 |
|
|
2018
Q4 | – | Sell |
-29,000
| Closed | -$3.57M | – | 656 |
|
|
2018
Q3 | $3.57M | Buy |
+29,000
| New | +$3.57M | 0.22% | 141 |
|
|
2018
Q1 | – | Sell |
-31,500
| Closed | -$2.44M | – | 481 |
|
|
2017
Q4 | $2.44M | Buy |
+31,500
| New | +$2.44M | 0.25% | 143 |
|
|
2017
Q2 | – | Sell |
-300
| Closed | -$13K | – | 642 |
|
|
2017
Q1 | $13K | Buy |
+300
| New | +$13K | ﹤0.01% | 475 |
|
|
2015
Q4 | – | Sell |
-1,000
| Closed | -$40K | – | 637 |
|
|
2015
Q3 | $40K | Buy |
+1,000
| New | +$40K | 0.03% | 362 |
|
|
2015
Q2 | – | Sell |
-6,700
| Closed | -$266K | – | 621 |
|
|
2015
Q1 | $266K | Buy |
+6,700
| New | +$266K | 0.44% | 73 |
|